- Home»
- The Billing Beat Newsletter»
- BCBS Kansas – Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
BCBS Kansas – Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
March 7, 2022Effective 02-22-2022
Updated Policy Section:
- Removed section A9 “Personal history of cancer and to aid in systemic therapy decision-making for PARP-inhibitors for human epidermal receptor 2 (HER2)-negative metastatic and HER2-negative early stage, high-risk breast cancer (see Policy Guidelines)”
Updated Policy Guidelines:
- Added new Section A:“Genetic testing for BRCA1 and BRCA2 variants in breast cancer-affected individuals who are considering systemic therapy is addressed separately in BCBSKS medical policy Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer”
- Removed Section D: “Breast Cancer Risk Groups”
Updated Coding Section:
- Added ICD 10 codes: D07.30-D07.39 and C79.89
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://www.bcbsks.com/medical-policies/germline-genetic-testing-brca1-or-brca2-hereditary-breastovarian-cancer-syndrome-2022-02-22